Correlation between Metabolic Syndrome and Gastric Cancer: Results of an Evidence-Based Strategy in Oriental Populations

Tong Liang; Junhong Wang; Zhenhua Gao; Mingxu Da

doi:10.2174/0113862073290567240506162553

Correlation between Metabolic Syndrome and Gastric Cancer: Results of an Evidence-Based Strategy in Oriental Populations

Comb Chem High Throughput Screen. 2024 May 17. doi: 10.2174/0113862073290567240506162553. Online ahead of print.

Authors

Tong Liang^{1

2}, Junhong Wang^{1

3}, Zhenhua Gao⁴, Mingxu Da^{1

2}

Affiliations

¹ The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, 730000, China.
² Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou, Gansu, 730000, China.
³ Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Baiyin, Baiyin, Gansu, 730900, China.
⁴ The First People's Hospital of Baiyin Hepatobiliary and Pancreatic Surgery, Baiyin, China.

PMID: 38766829
DOI: 10.2174/0113862073290567240506162553

Abstract

Background: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, including abdominal obesity, hyperglycemia, hypertension, and dyslipidemia. Gastric cancer (GC) is a common malignancy with significant mortality rates. The relationship between MetS and GC risk remains controversial. This systematic review and meta-analysis aimed to evaluate the correlation between MetS and GC.

Methods: Case-control studies investigating the association between MetS and GC were obtained from various databases, including China National Knowledge Infrastructure (CNKI), SinoMed, Embase, Web of Science, The Cochrane Library, and PubMed. The search was performed from the inception of each database up until September, 2023. Two researchers independently screened the literature, extracted data, and assessed the quality of the included studies. A meta-analysis of the included literature was conducted using Stata 12.0 software. The study protocol is registered in PROSPERO (CRD42023490410).

Results: A total of eight studies involving a combined sample size of forty-four thousand eight hundred and seventy participants were included in the meta-analysis. The findings revealed that the risk of developing GC was not significantly associated with body mass index, triglycerides, hypertension, high fasting glucose, or MetS. However, it was found to be positively correlated with high-density lipoprotein cholesterol (OR = 1.69, 95%CI: 1.35-2.12).

Conclusion: This meta-analysis suggests that MetS is not significantly associated with an increased risk of GC. The risk of GC increases with the presence of individual MetS components, such as high-density lipoprotein cholesterol. Therefore, GC prevention strategies should include lifestyle modifications and targeted interventions to manage MetS and its components.

Trial registration: CRD42023490410 (PROSPERO).

Keywords: Metabolic syndrome; gastric cancer; hyperglycemia; hypertension.; meta-analysis.

Publication types

Meta-Analysis